retatrutide type 2 diabetes trial results 2024 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending retatrutide type 2 diabetes phase

Low blood sugar is rare in people without diabetes

These effects are generally mild with well-formulated preparations but can become significant with certain absorption enhancers

doi: 10.1016/j.kint.2024.08.023 34 PerkovicVTuttleKRRossingPMahaffeyKWMannJFEBakrisGet al

The clinical reasons are weight loss plateau, comorbidity benefit not achieved on tirzepatide, or interest in retatrutides larger weight loss magnitude

These findings suggest that the addition of GLP-1 receptor agonists to metformin therapy may mitigate certain serious adverse effects associated with metformin monotherapy

It has chicken, which ups the protein content, helping to keep you satisfied even when you only eat a small portion